Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2026.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Par Drugs and Chemicals Limited held its Board Meeting on May 14, 2026 and approved its audited financial results for Q4 and FY2025-26 ending March 31, 2026. The auditors issued an UNMODIFIED opinion on the financial statements. The company declared bonuses of Rs. 25.14 lakh to employees (10% of basic salary) in April 2026. The Board authorized investments up to Rs. 90 crore in liquid funds, arbitrage funds, and fixed deposits. Banking facilities with Kotak Mahindra Bank were renewed at Rs. 161 lakh with no changes. A motor vehicle was approved for sale at approximately Rs. 1.50 lakh. CRITICAL: The Auditor's Report highlights a Key Audit Matter regarding SEBI issuing an Ex-Parte Interim Order followed by a Confirmatory Order restraining the implementation of a proposed Business Transfer Arrangement (BTA) involving slump sale of the company's primary business to a related party. The company is evaluating legal remedies to challenge these orders.
While the financial results show clean books with unmodified audit opinion, the SEBI restraining order on the business transfer is a significant regulatory concern that could impact future operations and strategy. Investors should monitor ongoing SEBI proceedings closely as the outcome may materially affect the company's business structure and going concern assessment.